Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Appetite-suppressant drugs and heart valve abnormalities.
Autore:
Adams, C; Cohen, A;
Indirizzi:
Ctr Hosp Univ St Antoine, Serv Cardiol, F-75571 Paris 12, France Ctr Hosp Univ St Antoine Paris France 12 rdiol, F-75571 Paris 12, France Ctr Hosp Victor Dupouy, Serv Cardiol, F-95107 Argenteuil, France Ctr Hosp Victor Dupouy Argenteuil France F-95107 5107 Argenteuil, France
Titolo Testata:
ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
fascicolo: 9, volume: 92, anno: 1999,
pagine: 1213 - 1219
SICI:
0003-9683(199909)92:9<1213:ADAHVA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
FRE
Soggetto:
PRIMARY PULMONARY-HYPERTENSION; FENFLURAMINE-PHENTERMINE; OBESE PATIENTS; DISEASE; ECHOCARDIOGRAPHY; REGURGITATION; RISK; DEXFENFLURAMINE; PREVALENCE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Cohen, A Ctr Hosp Univ St Antoine, Serv Cardiol, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France Ctr Hosp Univ St Antoine 184 Rue Faubourg St Antoine Paris France 12
Citazione:
C. Adams e A. Cohen, "Appetite-suppressant drugs and heart valve abnormalities.", ARCH MAL C, 92(9), 1999, pp. 1213-1219

Abstract

Serotoninergic appetite-suppressant drugs, fenfluramine and dexfenfluramine, were withdrawn from the market in September 1997 on account of two majorcardiopulmonary complications : primary pulmonary hypertension and valvular regurgitation. The valvular heart diseases involve mainly left-sided valves, and contraryto physiological valvular regurgitations, they appear mostly on the aorticvalve, Prolonged exposure (> 3 months) appears to confer a higher risk of cardiac valve involvement. Pathological features are similar to carcinoid or ergot alkaloid-induced valve diseases, and suggest a common pathophysiological mechanism which would also explain pulmonary hypertension by the toxic effect of high levels of circulating serotonin. After the first reports documenting a dramatically high prevalence of valvular side effects (up to 33% according to the Food and Drug Administration), recent studies reported a lower prevalence and severity, The long-term outcome and the real incidence are unknown and require further research and epidemiological data. A clinical survey of the patients exposed to serotoninergic appetite-suppressants is necessary, to be repeated 6 to 8 months later in the absence of an initial cardiac murmur. Doppler echocardiographic examination should be performed after prolonged exposure (> 3 months) or a high dosage of these drugs, in circumstances such as the presence of cardiovascular symptoms, a cardiac murmur, or an uncertain cardiac examination because of weight of patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:32:43